Ionis Pharmaceuticals (IONS)
Over the next 13 weeks, Ionis Pharmaceuticals has on average historically risen by 7% based on the past 26 years of stock performance.
Ionis Pharmaceuticals has risen higher by an average 7% in 12 of those 26 years over the subsequent 13 week period, corresponding to a historical probability of 46%
The holding period that leads to the greatest annualized return for Ionis Pharmaceuticals, based on historical prices, is 4 weeks. Should Ionis Pharmaceuticals stock move in the future similarly to its average historical movement over this duration, an annualized return of 54% could result.
Madrigal Pharmaceuticals (MDGL)
Over the next 13 weeks, Madrigal Pharmaceuticals has on average historically fallen by 6.5% based on the past 11 years of stock performance.
Madrigal Pharmaceuticals has fallen lower by an average 6.5% in 9 of those 11 years over the subsequent 13 week period, corresponding to a historical probability of 81%
The holding period that leads to the greatest annualized return for Madrigal Pharmaceuticals, based on historical prices, is 39 weeks. Should Madrigal Pharmaceuticals stock move in the future similarly to its average historical movement over this duration, an annualized return of 109% could result.
Regeneron Pharmaceuticals, Inc. (REGN)
Over the next 13 weeks, Regeneron Pharmaceuticals, Inc. has on average historically risen by 9.8% based on the past 27 years of stock performance.
Regeneron Pharmaceuticals, Inc. has risen higher by an average 9.8% in 15 of those 27 years over the subsequent 13 week period, corresponding to a historical probability of 55%
The holding period that leads to the greatest annualized return for Regeneron Pharmaceuticals, Inc., based on historical prices, is 4 weeks. Should Regeneron Pharmaceuticals, Inc. stock move in the future similarly to its average historical movement over this duration, an annualized return of 73% could result.
ProShares UltraPro Nasdaq Biotechnology (UBIO)
Over the next 13 weeks, ProShares UltraPro Nasdaq Biotechnology has on average historically risen by 33.1% based on the past 2 years of stock performance.
ProShares UltraPro Nasdaq Biotechnology has risen higher by an average 33.1% in 2 of those 2 years over the subsequent 13 week period, corresponding to a historical probability of 100%
The holding period that leads to the greatest annualized return for ProShares UltraPro Nasdaq Biotechnology, based on historical prices, is 4 weeks. Should ProShares UltraPro Nasdaq Biotechnology stock move in the future similarly to its average historical movement over this duration, an annualized return of 197% could result.
May 15th Daily Market Comments
Yesterday’s potential reversal signals in the market indexes are being confirmed Today. An expected pullback to the T-line has already been experienced in the NASDAQ and S&P 500. Both indexes have touched the T-line and showing support. Numerous stocks sold off on today’s early trading but are now coming back up. This would imply today as a profit-taking day, not necessarily a market reversal. Continue to watch to see what the indexes do at the T-line.